BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 26329766)

  • 21. Characterization of humoral and cellular immunity to rubella vaccine in four distinct cohorts.
    Lambert ND; Haralambieva IH; Ovsyannikova IG; Larrabee BR; Pankratz VS; Poland GA
    Immunol Res; 2014 Jan; 58(1):1-8. PubMed ID: 24375276
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kinetics of antibody and memory B cell responses after MMR immunization in children and young adults.
    Kakoulidou M; Ingelman-Sundberg H; Johansson E; Cagigi A; Farouk SE; Nilsson A; Johansen K
    Vaccine; 2013 Jan; 31(4):711-7. PubMed ID: 23174196
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Measles-mumps-rubella revaccination; 18 months vs. 4-6 years of age: potential impacts of schedule changes.
    Saffar MJ; Fathpour GR; Parsaei MR; Ajami A; Khalilian AR; Shojaei J; Saffar H
    J Trop Pediatr; 2011 Oct; 57(5):347-51. PubMed ID: 21078605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella.
    Nascimento Silva JR; Camacho LA; Siqueira MM; Freire Mde S; Castro YP; Maia Mde L; Yamamura AM; Martins RM; Leal Mde L;
    Vaccine; 2011 Aug; 29(37):6327-34. PubMed ID: 21640779
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polymorphisms in HLA-DPB1 are associated with differences in rubella virus-specific humoral immunity after vaccination.
    Lambert ND; Haralambieva IH; Kennedy RB; Ovsyannikova IG; Pankratz VS; Poland GA
    J Infect Dis; 2015 Mar; 211(6):898-905. PubMed ID: 25293367
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Associations between markers of cellular and humoral immunity to rubella virus following a third dose of measles-mumps-rubella vaccine.
    Crooke SN; Ovsyannikova IG; Kennedy RB; Warner ND; Poland GA
    Vaccine; 2020 Nov; 38(50):7897-7904. PubMed ID: 33158591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
    Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
    Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Waning antibody levels and avidity: implications for MMR vaccine-induced protection.
    Kontio M; Jokinen S; Paunio M; Peltola H; Davidkin I
    J Infect Dis; 2012 Nov; 206(10):1542-8. PubMed ID: 22966129
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of serum antibodies against measles, mumps and rubella after primary measles, mumps and rubella (MMR) vaccination in children.
    Rafiei Tabatabaei S; Esteghamati AR; Shiva F; Fallah F; Radmanesh R; Abdinia B; Shamshiri AR; Khairkhah M; Shekari Ebrahimabad H; Karimi A
    Arch Iran Med; 2013 Jan; 16(1):38-41. PubMed ID: 23273235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Associations between measles vaccine immunity and single-nucleotide polymorphisms in cytokine and cytokine receptor genes.
    Dhiman N; Ovsyannikova IG; Cunningham JM; Vierkant RA; Kennedy RB; Pankratz VS; Poland GA; Jacobson RM
    J Infect Dis; 2007 Jan; 195(1):21-9. PubMed ID: 17152005
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extinction of the human leukocyte antigen homozygosity effect after two doses of the measles-mumps-rubella vaccine.
    St Sauver JL; Dhiman N; Ovsyannikova IG; Jacobson RM; Vierkant RA; Pankratz VS; Jacobsen SJ; Poland GA
    Hum Immunol; 2005 Jul; 66(7):788-98. PubMed ID: 16112026
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of rubella-specific humoral immunity following two doses of MMR vaccine using proteome microarray technology.
    Haralambieva IH; Gibson MJ; Kennedy RB; Ovsyannikova IG; Warner ND; Grill DE; Poland GA
    PLoS One; 2017; 12(11):e0188149. PubMed ID: 29145521
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
    Zäch K; Nicoara C; Germann D; Matter L
    Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of vitamin A and D receptor gene polymorphisms/haplotypes on immune responses to measles vaccine.
    Ovsyannikova IG; Haralambieva IH; Vierkant RA; O'Byrne MM; Jacobson RM; Poland GA
    Pharmacogenet Genomics; 2012 Jan; 22(1):20-31. PubMed ID: 22082653
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlates of lymphoproliferative responses to measles, mumps, and rubella (MMR) virus vaccines following MMR-II vaccination in healthy children.
    Dhiman N; Ovsyannikova IG; Jacobson RM; Vierkant RA; Pankratz VS; Jacobsen SJ; Poland GA
    Clin Immunol; 2005 May; 115(2):154-61. PubMed ID: 15885638
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human leukocyte antigen class II alleles and rubella-specific humoral and cell-mediated immunity following measles-mumps-rubella-II vaccination.
    Ovsyannikova IG; Jacobson RM; Vierkant RA; Jacobsen SJ; Pankratz VS; Poland GA
    J Infect Dis; 2005 Feb; 191(4):515-9. PubMed ID: 15655774
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants.
    Spoulou V; Giannaki M; Vounatsou M; Bakoula C; Grafakos S
    Bone Marrow Transplant; 2004 Jun; 33(12):1187-90. PubMed ID: 15077129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Durability of humoral immune responses to rubella following MMR vaccination.
    Crooke SN; Riggenbach MM; Ovsyannikova IG; Warner ND; Chen MH; Hao L; Icenogle JP; Poland GA; Kennedy RB
    Vaccine; 2020 Dec; 38(51):8185-8193. PubMed ID: 33190948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SLAM and DC-SIGN measles receptor polymorphisms and their impact on antibody and cytokine responses to measles vaccine.
    Clifford HD; Richmond P; Khoo SK; Zhang G; Yerkovich ST; Le Souëf PN; Hayden CM
    Vaccine; 2011 Jul; 29(33):5407-13. PubMed ID: 21645571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.